ORNBV Orion Oyj

110.45USD100.70 EUR · HEL-0.69%Mkt Cap: 15.50B USDP/E: 21.52

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharm…

Institutional holders11 on file

Key Statistics

Company
Market Cap15.50B USD
Enterprise Value15.48B USD
Revenue (TTM)2.39B USD
Gross Profit1.33B USD
Net Income (TTM)548.73M USD
Revenue/Share16.96 USD
Last Price110.45 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees4.2K
CountryFI
SectorHealthcare
IndustryDrug Manufacturers - General
ISINFI0009014377
Valuation
P/E (Trailing)21.52
P/E (Forward)19.94
PEG5.73
EV/EBITDA15.96
EV/Revenue6.48
P/S6.49
P/B10.11
EPS (TTM)5.13 USD
EPS (Forward)5.54 USD
52W Range
63.6793% of range114.07
52W High114.07 USD
52W Low63.67 USD
Profitability
Gross Margin64.20%
Oper. Margin38.11%
EBITDA Margin40.63%
Profit Margin26.48%
ROE38.95%
ROA24.89%
ROIC35.08%
ROCE43.39%
Growth
Revenue Growth28.10%
Earnings Growth75.00%
Cash Flow & Leverage
Operating CF347.47M USD
CapEx (TTM)107.05M USD
FCF Margin12.47%
FCF Yield1.92%
Net Debt-20.62M USD
Net Debt/EBITDA-0.02
Net Debt/FCF-0.07
Balance Sheet
Debt/Equity0.24
Current Ratio2.72
Quick Ratio1.61
Book Value/Sh10.93 USD
Cash/Share1.13 USD
Dividends
Fwd Div Rate1.97 USD
Trail. Div Rate1.97 USD
Div. Yield1.78%
5Y Avg Yield2.89%
Payout Ratio36.75%
Ex-Div DateOct 19, 2026
Pay Date—
Analyst Consensus
Rating2.2 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)95.97 USD
Upside (mean)-13.1%
Target Range60.32 USD – 126.13 USD
60.32-13.1% to mean126.13
# Analysts6
Ownership
Shares Out.108.99M
Float122.99M
Insiders2.63%
Institutions46.63%
Technical
SMA 5098.21 (+12.5%)
SMA 20084.01 (+31.5%)
Beta0.23
S&P 52W Chg12.00%
Avg Vol (30d)163.70K
Avg Vol (10d)136.91K
Technical Indicators
RSI (14)66.6
MACD3.5765
MACD Signal4.1899
MACD Hist.-0.6134
BB Upper116.25 USD
BB Middle109.79 USD
BB Lower103.33 USD
BB Width11.77%
ATR (14)2.289 USD
Vol Ratio (20d)0.94x

About Orion (HEL: ORNBV)

›

Orion (HEL: ORNBV) is listed on Nasdaq Helsinki, where its shares trade in EUR. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 4,215 employees.

The shares were at 100.70 EUR on 19 November 2026, up 76.3% over 52 weeks. Its 52-week range is 58.05 EUR to 104.00 EUR: the price is 3.2% below the high and 73.5% above the low.

At a market capitalisation of 14.13B EUR, it trades at 21.5 times trailing earnings and 19.9 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 17% for ORNBV. It pays a dividend yielding 1.78% (it pays out 37% of its earnings), against a median of 2.43% among the dividend payers in that peer group.

Orion reports return on equity of 38.9%, an operating margin of 38.1% and revenue up 28.1% year over year.

It holds more cash than debt, a net cash position of 18.80M EUR. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 87.50 EUR is 13.1% below the current price. The next earnings report is expected on 17 February 2027.